Dr. Gregory A. Yanik
Claim this profileUniversity of Michigan Health
Studies Leukemia
Studies Acute Myeloid Leukemia
3 reported clinical trials
4 drugs studied
Area of expertise
1Leukemia
CD33 positive
HLA negative
RB1 positive
2Acute Myeloid Leukemia
CD33 positive
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Gregory A. Yanik is currently running
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
VCAR33
for Leukemia
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Recruiting1 award Phase 1 & 2
More about Gregory A. Yanik
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Gregory A. Yanik has experience with
- VCAR33
- Lactobacillus Plantarum
- Matched Unrelated Donor Hematopoietic Cell Transplantation (MUD-HCT)
- Haploidentical Hematopoietic Cell Transplantation (haploHCT)
Breakdown of trials Gregory A. Yanik has run
Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Graft-versus-Host Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory A. Yanik specialize in?
Gregory A. Yanik focuses on Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Leukemia has involved CD33 positive patients, or patients who are HLA negative.
Is Gregory A. Yanik currently recruiting for clinical trials?
Yes, Gregory A. Yanik is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Gregory A. Yanik has studied deeply?
Yes, Gregory A. Yanik has studied treatments such as VCAR33, Lactobacillus Plantarum, matched unrelated donor hematopoietic cell transplantation (MUD-HCT).
What is the best way to schedule an appointment with Gregory A. Yanik?
Apply for one of the trials that Gregory A. Yanik is conducting.
What is the office address of Gregory A. Yanik?
The office of Gregory A. Yanik is located at: University of Michigan Health, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.